Proapoptotic action of p53-Tom5 in p53-resistant A549 human non-small cell lung cancer cells through direct...

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Transcription-dependent apoptosis via p53 is impaired in alternative reading frame (ARF)-null cancers.
• ARF loss activates MDM2, leading to p53 degradation, hindering apoptosis.
• Targeting p53 to mitochondria offers a potential strategy to bypass this resistance.

Purpose of the Study:

• To investigate if targeted mitochondrial delivery of p53 can induce apoptosis in ARF-null lung cancer cells.
• To evaluate the efficacy of a p53-Tom5 fusion protein in suppressing proliferation and inducing mitochondrial dysfunction.

Main Methods:

• A549 (ARF-null) human non-small lung cancer cells were utilized.
• Cells were transfected with a plasmid encoding human wild-type p53 fused to the mitochondrial transmembrane domain of Tom5 (p53-Tom5).
• Cell proliferation, mitochondrial localization, mitochondrial dysfunction, and cytochrome c release were assessed.

Main Results:

• p53-Tom5 exclusively localized to mitochondria in A549 cells.
• p53-Tom5 significantly suppressed cancer cell proliferation, whereas wild-type p53 did not.
• Mitochondrial dysfunction and subsequent cytochrome c release were observed upon p53-Tom5 expression.

Conclusions:

• Targeting p53 to mitochondria via the Tom5 domain is effective in suppressing proliferation of ARF-null lung cancer cells.
• p53-Tom5 induces cancer cell death through direct mitochondrial dysfunction, bypassing ARF-mediated p53 degradation.
• This approach presents a novel therapeutic strategy for ARF-null lung cancers.